Kornimate/medical-research-clean huggingface dataset:
comparison of the pressure ulcer prevention effects of two mattresses with different support surfaces used in bedridden patients

Conditions: Pressure Ulcer; Nursing Caries

Summary: aim: this study was conducted to investigate the effectiveness of two types of mattresses with different support surfaces used in bedridden patients. method: the sample of this quasi-experimental study consisted of 60 patients according to the inclusion criteria. a group i and group ii of 30 patients each were formed from the sampled patients. for the patients in group i, a bed with a cube/block system and vibration (massage) feature was used. for the patients in group ii, a viscoelastic mattress was used. the data of the study were collected with the ''patient identification form'', ''braden scale'', ''pressure wound observation form'' and ''wound measurement chart''. number-percentage distributions, chi-square, fisher's exact probability test and mann-whitney-u tests were used to evaluate the data. implications for clinical practice: it was determined that the support surface used affected the pressure sore size and the mattress with cube/block system and vibration (massage) feature created smaller sized wounds in the sacrum, trochanter, malleolus and heel regions. in the sacrum, scapula, and heel regions, although not statistically significant in terms of wound stage and the number of patients who developed pressure sores, it was seen that the mattress with cube/block system and vibration (massage) feature was more effective.


Eligibility criteria:
inclusion criteria: * a "low risk" rating on the braden scale. * voluntary informed consent from conscious patients and consent from the legal guardian for unconscious or confused patients. * absence of pressure sores upon admission to the clinics. * a bmi (body mass index) not exceeding 30.00 (as classified by the world health organization). exclusion criteria: * the patient's bed was changed in less than ten days after inclusion in the study, * patient referral, * discharge * exhitus was the exclusion criteria.
effects of compression wear on muscle soreness

Conditions: Muscular Regeneration; Repeated Bout Effect of WB-EMS

Summary: the study address two main topics: 1. the effect of compression garment on whole-body electromyostimulation (wb-ems) induced muscle soreness in young adults 2. the repeated bout effect of one intense session of wb-ems as determined by various regeneration parameters

using a cross-over design we applied 2 intense wb-ems training sessions either with or without subsequent wearing of compression garments (long tights) for 5 days at baseline and after a washout period of 4 weeks. healthy young to middle aged athletes used compression garments immediately postexercise for 24 hours and further 12 h during the day. blood samples, questionnaires, resting metabolic rate and performance test were applied prior and 24, 48,72 and 96 h post-exercise consistently without wearing compression garments.

Eligibility criteria:
inclusion criteria: * healthy athletes with \>5 years of experience in competition balls sports and corresponding discipline specific resistance exercise exclusion criteria: * diseases and medication affecting muscle metabolism * contraindication for wb-ems
a study of ro5429083 alone or in combination with cytarabine in patients with acute myelogenous leukemia

Conditions: Myelogenous Leukemia, Acute

Summary: this multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of ro5429083 alone and in combination with cytarabine in patients with acute myelogenous leukemia. in part a, patients will receive multiple escalating doses of ro5429083 intravenously. in part b, patients will receive ro5429083 plus up to 4 cycles of cytarabine (1000 mg/m2 iv daily for 5 consecutive days). anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * histologically or cytologically confirmed, acute myelogenous leukemia (all subtypes except acute promyelotic leukemia) according to who criteria * eastern cooperative oncology group (ecog) performance status 0 to 2 * all non-hematological adverse events of any prior chemotherapy, surgery, or radiotherapy must have resolved to nci-ctc ae grade \< 2, except alopecia * adequate hepatic and renal function * patient must be willing to submit blood and bone marrow samples for pk and pd analyses and exploratory biomarkers exclusion criteria: * patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug, with the exception of hydroxyurea * history of allergic reactions attributed to components of cytarabine and/or the formulated product * current evidence of cns leukemia * increased qtc interval (qtc \> 470 ms), baseline resting bradycardia \< 45 beats per minute, or baseline resting tachycardia \< 100 beats per minute * family history of long qt syndrome or other risk factors for torsades de pointes, and/or the use of concomitant medications that prolong qt/qtc interval * uncontrollable intercurrent illness * pregnant or breast-feeding women * hiv-positive patients receiving anti-retroviral therapy * patients who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
promad: predicting therapeutic outcome of mandibular advancement device treatment in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the present research intends to focus clinically on selecting the right type of patient for mandibular advancement devices (mad) therapy using screening tools such as advanced imaging and computational methods based on ct-scan images as well as drug-induced sleep nasendoscopy techniques with simulation of the mandibular repositioning. the core of the research project relies on known and established methods accepted in several neighboring fields, but aims at the transfer of this knowledge by integrating it into this new domain. doing so, the proposed biomedical research is directed towards clinical applications that incorporate innovative developments on the level of the diagnosis and therapy of a specific disease, being obstructive sleep apnea syndrome (osas). furthermore, this study aims at registering objective compliance during mad therapy.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * body mass index (bmi) ≤ 35 kg/m² * osas, as defined by the american academy of sleep medicine task force * apnea-hypopnea index (ahi) \< 50 exclusion criteria: * other sleep disorders (i.e. parasomnias) * invasive upper airway surgery for sleep-disordered breathing * known genetic disorders with craniofacial and/or upper airway malformations * use of benzodiazepine and/or antidepressants * known history of psychiatric disease * known history of fibromyalgia and/or chronic fatigue syndrome * dental contra-indications: functional restrictions of the temporomandibular joint, insufficient dentition with pathological changes, insufficient retention for mad use

Keywords: osas american academy of sleep medicine task force
vitamin d 24'000 iu for oral intermittent supplementation

Conditions: Vitamin D Deficiency

Summary: vitamin d deficiency (defined as 25(oh)-vitamin d serum level \ 75 nmol/l (secondary outcome). the investigators will use newly developed soft capsules and alcoholic solution, which are commercially available in switzerland.

group control, alcoholic drinking solution: 5 ml of an alcoholic drinking solution with 24'000 iu vitamin d p.o. once a month for 3 months (3 doses). group imp, capsules: one capsule with 24'000 iu vitamin d p.o. once a month for 3 months (3 doses). group imp + loading dose, loading dose: one capsule with 24'000 iu vitamin d p.o. once a week during an individually calculated number of weeks. all 3 groups: measurement of vitamin d in serum before therapy and one week after the last dose.

Eligibility criteria:
inclusion criteria: * vitamin d deficiency by serum level \<50 nmol/l exclusion criteria: * hypercalcaemia

Keywords: optimal vitamin d value
improving parental knowledge: supplementation of prematurity counseling with written information

Conditions: Premature Birth

Summary: pregnant women who receive study counseling which includes gestational age specific written information in addition to the verbal counseling will have better knowledge of problems and outcomes of prematurity than women who receive standard counseling which consists of only verbal counseling.


Eligibility criteria:
inclusion criteria: * english speaking pregnant women who are between 23-34 weeks of gestation * who are 18 years and older * open to all ethnic groups. * admitted in preterm labor to froedtert and waukesha hospitals labor and delivery unit. exclusion criteria: * pregnant women who are known to have infants with congenital anomalies or other associated conditions apart from prematurity that could be a significant factor to the outcome of the baby. * pregnant women who have been included in this study and discharged at some point and again admitted for preterm labor will be excluded from the study. * if a participant delivers before completing the parent knowledge questionnaire, she will be excluded.

Keywords: prematurity counseling for pregnant women and their family
pharmacokinetics of sotrovimab as pre-exposure prophylaxis for covid-19 in hematopoietic stem cell transplant recipients, covidmab study

Conditions: COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this phase i trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients. sotrovimab is a monoclonal antibody that may target and bind to a specific protein on sars-cov-2 and block its viral attachment and entry into human cells. this may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with sars-cov-2 in hematopoietic stem cell transplant recipients.

outline: patients receive sotrovimab intravenously (iv) over 30 minutes within 1-7 days prior to the start of pre-transplant conditioning. patients also undergo blood and nasal swab sample collection throughout the trial. after completion of study treatment, patients are followed up for 24 weeks.

Eligibility criteria:
inclusion criteria: * patients (or legally authorized representative if applicable) must be capable of understanding and providing a written informed consent * patients must be at least 18 years of age, of any gender, race, or ethnicity * patients must be undergoing hct (any donor or stem cell source including autologous or cord blood) * history of prior transplants are permitted * history of covid-19, history of vaccination for sars-cov-2, positive polymerase chain reaction (pcr) of a respiratory specimen for sars-cov-2 as long as it is not within four weeks from conditioning, or seropositivity for sars-cov-2 are permitted * history of sars-cov-2 infection or vaccination of the donor are permitted. * post-enrollment vaccination is anticipated and permitted * administration of intravenous immunoglobulin therapy (ivig) before or during the study is permitted exclusion criteria: * signs or symptoms of uncontrolled, active infection * positive pcr result for sars-cov-2 within four weeks of scheduled conditioning * pregnant or breastfeeding (this population is generally not cleared for transplant) * pregnancy test is obtained as part of pre-transplant evaluation in women of child-bearing potential at arrival to transplant and again within 7 days of conditioning and will be confirmed as negative by review of the chart * previous anaphylaxis or severe hypersensitivity reaction, including angioedema, to a mab * previous reaction to a mab that required medical attention * participants of other clinical studies that preclude the use of other investigational compounds * participants who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of the protocol or unlikely to survive to the end of study
double-blind randomized clinical trial of transcranial magnetic stimulation in chronic migraine

Conditions: Chronic Migraine

Summary: the purpose of this study is to determine whether active repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex is safe and effective for preventive treatment of chronic migraine, compared to placebo repetitive transcranial magnetic stimulation.

patients with chronic migraine according to the criteria of the international headache society will be randomized to either active repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex or placebo repetitive transcranial magnetic stimulation, in a total of 23 sessions of treatment (15 sessions in the first month and 8 sessions in the second month of treatment). outcomes will be evaluated at baseline, after one, two months after treatment, and one month after end of treatment

Eligibility criteria:
inclusion criteria: * chronic migraine according to the criteria of the international headache society * no change in prophylactic medication in the past 3 months exclusion criteria: * other neurological disorders * bipolar disorder * alcohol or drug dependence in the past 2 months * suicidal ideation, psychotic symptoms * contraindications to transcranial magnetic stimulation (cardiac pacemaker, implanted electronic devices, metal in the skull, skull fractures, history of seizures) * use of antidepressants in the past 4 weeks * pregnancy or lack of birth-control method in women of childbearing age

Keywords: migraine
prospective investigation of antithrombin iii deficiency in adult patients with ecmo

Conditions: Antithrombin III Deficiency; Extracorporeal Membrane Oxygenation Complication

Summary: there are publications showing a decrease in antithrombin iii levels of continuous flow and routine heparin therapy in adult patients undergoing extracorporeal membrane oxygenation (ecmo) however, there is not enough data. one of the multifactorial causes affecting bleeding / thrombosis complications and act levels may be acquired antithrombin iii deficiency. the antithrombin iii activity test results from the patients to be included in the study during the study will be recorded immediately after ecmo run, at the 24th hour before the heparin infusion start and at the 48th, 72nd and 96th hours following the follow-up. the results will be analyzed to figure out a relationship between decreasing antithrombin 3 values and thrombotic events.

ecmo is applied in patients with acute severe heart or lung failure. the treatment protocol of patients undergoing ecmo is carefully arranged against the risk of bleeding / thrombosis. according to the general protocol, heparin infusion therapy is started at the 24th hour after ecmo application. the risk of bleeding / thrombosis is avoided by adjusting the heparin infusion dose with activated clotting time (act) control. however, over time, thrombocytopenia and fluctuations in act level are observed in patients. it may be necessary to increase the dose of heparin given during the prolonged period. one of the multifactorial causes affecting bleeding / thrombosis complications and act levels may be acquired antithrombin iii deficiency. there are publications reporting a decrease in antithrombin iii levels of continuous flow and routine heparin therapy in adult patients undergoing ecmo; however, there is not enough data. the antithrombin iii activity test results from the patients to be included in the study during the study will be recorded immediately after ecmo run, at the 24th hour before the heparin infusion start and at the 48th, 72nd and 96th hours following the follow-up. the results will be analyzed to figure out a relationship between decreasing antithrombin 3 values and thrombotic events.

Eligibility criteria:
inclusion criteria: * being over the age of 18 * patients with ecmo run for 3 days or more (to be able to determine at least 3 antithrombin 3 levels) exclusion criteria: * patients with ecmo run less than 3 days

Keywords: antithrombin iii, ecmo
contralateral effects of russian current on adolescent athlete

Conditions: Treatment Side Effects

Summary: the strength loss associated with immobilization causes long term decreases in performance and loss of hours of participation for athletes during rehabilitation period to regain a competitive form. therefore, reducing such effects throughout the immobilization period is highly preferable. cross-educational strength transfer to the inactive muscle by means of unilateral strength training may provide an opportunity to avoid strength loss and atrophy.

after injury and/or surgery, neuromuscular electrical stimulation is widely used to train muscles and enhance muscle strength. and some studies have found it to be superior to voluntary exercise after immobilization . one of the preferred common nmes techniques for muscle strengthening is the russian current (rc) it stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy. while some studies exist to confirm the efficacy of this current in the russian language, there is very little evidence to support its use in english literature. the aim of our study is to investigate the effectiveness of cross education of russian current on the strength of the contralateral inactive biceps and triceps muscles of the affected elbow in pediatrics athletes to decrease some of the negative effects of immobilization on muscle tissue and enhance recovery.

Eligibility criteria:
inclusion criteria: * 1 year experience in tennis training * diagnosis of tennis elbow exclusion criteria: * any contraindication to the application of electrotherapy * upper limb surgery

Keywords: tennis elbow cross-training electrical stimulation
actions to decrease disparities in risk and engage in shared support for blood pressure control (address-bp) in blacks

Conditions: Hypertension (HTN)

Summary: to use practice facilitation (pf) + community health worker (chw) facilitation as a practical and sustainable implementation strategy to support the implementation and evaluation of three multi-level evidence-based interventions \[nurse case management (ncm), remote blood pressure monitoring (rbpm), and social determinants of health (sdoh) support\] delivered as an integrated community-clinic linkage model \[practice support and community engagement (pace) to address patient-, physician-, health system-, and community-level barriers to hypertension (htn) control in blacks across 25 primary practices within nyu langone health in new york city (nyc) and, in partnership with an established community-clinic-academic advisory board and healthfirst (nyc's largest medicaid payer). the goal for the uh3 implementation phase (years 4-7, intervention) is to evaluate a stepped-wedge cluster rct of 25 primary care practices in black patients with uncontrolled hypertension (htn) the goal for the uh3 implementation phase (years 4-7, intervention) is to evaluate a stepped-wedge cluster rct of 20 primary care practices in black patients with uncontrolled hypertension (htn).


Eligibility criteria:
uh3 implementation phase (years 4 - 7): intervention inclusion criteria: patients are eligible if he/she: 1. identifies as black (through ehr code or self-report) 2. is 18-85 years of age 3. has a diagnosis of htn (identified by icd-10 codes for htn) 4. prescribed an antihypertensive medication(s) 5. has a clinic bp \> 130/80 mmhg exclusion criteria: patients will be ineligible for the study if they: 1. are deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks) 2. participate in other hypertension-related clinical trials 3. have significant psychiatric comorbidity or reports of substance abuse (as documented in the ehr) 4. plan to discontinue care at the site within the next 12 months; or 5. are pregnant or planning to become pregnant in the next 12 months implementation evaluation 1. nyulh primary care provider (md/do, np), clinical director, site administrator, medical assistant, or administrative staff employed at the participating practices and interacts with at least five patients with a diagnosis of hypertension; or 2. nyulh nurse case manager within centralized service; or 3. staff and leadership of community- and faith-based organizations serving the black community; or 4. nyulh organizational leadership; or 5. nyulh project staff: community health workers/chw supervisor/practice facilitators; and 6. able and willing to provide consent exclusion criteria: 1. refusal to participate
effectiveness of home based early intervention of extremely premature infant by parent

Conditions: Preterm; Extreme Prematurity; Early Intervention; Developmental Delay; Motor Outcome; Home Exercise; Parents

Summary: this study is to prove the effectiveness of home based early intervention of extremely premature infant by parent.

the perpose of this study to prove the significance of the hypothesis that there will be a significant improvement in motor development when remote tele-rehabilitation treatment is performed for extremely premature infants. the investigators plan to recruit subjects who meet the inclusion criteria and do not meet the exclusion criteria from among extremely premature infants born at samsung hospital, seoul, korea, whose gestational age is from 23 weeks to 28 weeks. the target number of n is 110, 55 per group. after randomization into an intervention group and a control group, the intervention group get the intervention starting at 0 months of correctional age and runs for 3 months. in both groups, motor outcomes are measured at the time of enrollment, at 3 months of correction age, 6 months of correction age and 12 months of correction age

Eligibility criteria:
inclusion criteria: * extreme premature baby (gestationl age 23\~28 weeks) * corrected age under one month at the time of enroll of this study * children of those who voluntarily decided to participate after hearing detailed explanations about this study and gave their written consent. * children whose parents are korean exclusion criteria: * congenital anomalies in the central nervous system * hereditary diseases * chromosomal abnormalities (down syndrome, etc.) * stage 3 or more intraventricular hemorrhage * if surgery was performed for hydrocephalus * leukomalacia confirmed by ultrasound examination (not applicable to increase in white matter shading) * neonatal asphyxia * other central nervous system diseases * if taking medications for convulsions or epilepsy * metabolic disease * in the case of premature infants undergoing surgery for retinal disease * hearing loss * in case of surgery due to complex congenital anomaly or planned operation (not excluded if surgery is not required) * in case of oxygen dependence due to lung disease in premature infants * musculoskeletal disorders (hip dislocation, polyarthrosis, etc.) * neuromuscular disease, etc. * those whose family has social problems * those whose parents cannot participate in this study * those who have other serious complications that cannot proceed with the study